Modulators of chemokine receptors

1. A compound having the Formula (A):

wherein

B is selected from the group consisting of furanyl, thiophenyl, oxazolyl, phenyl, pyridyl, pyrimidinyl and pyrazinyl, each of which is optionally substituted with R 1a , R 1b , and R 2 which are independently selected from the group consisting of halogen, CN, C 1-4 alkyl, C 1-4 alkoxy and C 1-4 haloalkyl;

R 3 is a member selected from the group consisting of H and D;

R 4 is a member selected from the group consisting of H, C 1-8 alkyl, OH, —NR a R b , —C 1-4 alkoxy, and Y; wherein the C 1-8 alkyl is optionally substituted with halogen, —CN, —CO 2 R a , —CONR a R b , —C(O)R a , OC(O)NR a R b , —NR a C(O)R b , —NR a C(O) 2 R c , —NR a C(O)NR a R b , —NR a R b , —OR a , —S(O) 2 NR a R b , —NR a S(O) 2 R b and Y, wherein Y is a 4 to 8 membered cycloheteroalkyl group or a 3 to 8 membered cycloalkyl group or a 5- or 6-membered aryl or heteroaryl group any of which is optionally substituted with from 1 to four substituents selected from halogen, oxo, —CN, —C 1-6 alkyl, —C 1-6 alkoxy, —C 1-6 hydroxyalkyl, —C 1-6 haloalkyl, O—C 1-6 haloalkyl, —C 1-4 alkyl-O—C 1-4 alkyl, —C 1-6 alkyl-NR a R b , —C 1-6 alkyl-CO 2 H, —C 1-6 alkyl-CO 2 R a , —C 1-6 alkyl-CONR a R b , —C 1-6 alkyl-C(O)R a , —C 1-6 alkyl-OC(O)NR a R b , —C 1-6 alkyl-NR a C(O)R b , —C 1-6 alkyl-NR a C(O) 2 R c , —C 1-6 alkyl-NR a C(O)NR a R b , —C 1-6 alkyl-OR a , —C 1-6 alkyl-S(O) 2 NR a R b , —C 16 alkyl-NR a S(O) 2 R b , —CO 2 R a , —CONR a R b , —C(O)R a , —OC(O)NR a R b , —NR a C(O)R b , —NR a C(O) 2 R c , —NR a C(O)NR a R b , —NR a R b , —OR a , —S(O) 2 NR a R b , —NR a S(O) 2 R b , —CH 2 CO 2 R a ; each R a and R b is independently selected from hydrogen, C 1-4 alkyl, C 1-4 hydroxyalkyl and C 1-4 haloalkyl, and R is selected from C 1-4 alkyl, C 1-4 hydroxyalkyl and C 1-4 haloalkyl; and wherein the 4 to 8 membered cycloheteroalkyl group and the 3 to 8 membered cycloalkyl group may additionally be optionally substituted with oxo;

R 5a and R 5b are each members independently selected from the group consisting of H, halogen, C 1-4 alkyl, —C 1-4 haloalkyl, O—C 1-4 haloalkyl, C 1-4 alkoxy, CO 2 H and CN;

R 6a and R 6b are each members independently selected from the group consisting of H, C 1-4 alkyl, C 1-4 hydroxyalkyl and C 1-4 haloalkyl; or optionally R 6a and R 6b are taken together to form oxo (═O) or a 4 to 6 membered cycloheteroalkyl group or a 3 to 6 membered cycloalkyl group;

R 7 is a member selected from the group consisting of methyl, ethyl and C 1-2 haloalkyl; and

the subscript n is 1 or 2;

or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, tautomer or rotamer thereof.

2. A compound of claim 1 having the Formula (I):

wherein

B is selected from the group consisting of furanyl, oxazolyl, phenyl, pyridyl, pyrimidinyl and pyrazinyl, each of which is optionally substituted with R 1a , R 1b , and R 2 which are independently selected from the group consisting of halogen, CN, C 1-4 alkyl, C 1-4 alkoxy and C 1-4 haloalkyl;

R 3 is a member selected from the group consisting of H and D;

R 4 is a member selected from the group consisting of H, C 1-8 alkyl, and Y; wherein the C 1-8 alkyl is optionally substituted with halogen, —CN, —CO 2 R a , —CONR a R b , —C(O)R a , OC(O)NR a R b , —NR a C(O)R b , —NR a C(O) 2 R c , —NR a C(O)NR a R b , —NR a R b , —OR a , —S(O) 2 NR a R b , —NR a S(O) 2 R b and Y, wherein Y is a 5- or 6-membered aryl or heteroaryl group with from one to four substituents selected from halogen, —CN, —C 1-4 alkyl, —C 1-4 alkoxy, —C 1-4 hydroxyalkyl, —C 1-4 haloalkyl, OCF 3 , —CO 2 R a , —CONR a R b , —C(O)R a , —OC(O)NR a R b , —NR a C(O)R b , —CH 2 CO 2 R a ; and each R a and R b is independently selected from hydrogen, C 1-4 alkyl, C 1-4 hydroxyalkyl and C 1-4 haloalkyl, and R is selected from C 1-4 alkyl, C 1-4 hydroxyalkyl and C 1-4 haloalkyl;

R 5a and R 5b are each members independently selected from the group consisting of H, halogen, C 1-4 alkyl, C 1-4 alkoxy, CO 2 H and CN;

R 6a and R 6b are each members independently selected from the group consisting of H, C 1-4 alkyl, C 1-4 hydroxyalkyl and C 1-4 haloalkyl; or optionally R 6a and R 6b are taken together to form oxo (═O); and

the subscript n is 1 or 2;

or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, tautomer or rotamer thereof.

3. A compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, tautomer or rotamer thereof, wherein B is selected from the group consisting of:

4. A compound of claim 3 , or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, tautomer or rotamer thereof, wherein B is selected from the group consisting of:

5. A compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, tautomer or rotamer thereof, wherein B is furanyl or oxazolyl, each of which is optionally substituted with R 1a and R 1b , which are independently selected from the group consisting of halogen, CN, C 1-4 alkyl, C 1-4 alkoxy and C 1-4 haloalkyl.

6. A compound of claim 5 or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, tautomer or rotamer thereof, wherein B is furanyl substituted with R 1a which is CH 3 or Cl and optionally substituted with R 1b which is CH 3 .

7. A compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, tautomer or rotamer thereof, wherein R 3 is H.

8. A compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, tautomer or rotamer thereof, wherein each of R 5a and R 5b is independently selected from the group consisting of H, CH 3 , Cl and F.

9. A compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, tautomer or rotamer thereof, wherein

is selected from the group consisting of:

10. A compound of claim 9 , or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, tautomer or rotamer thereof, wherein

is selected from the group consisting of:

11. A compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, tautomer or rotamer thereof, wherein each of R 6a and R 6b is independently selected from the group consisting of H and C 1-2 alkyl.

12. A compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, tautomer or rotamer thereof, wherein

is independently selected from the group consisting of

13. A compound of claim 12 , or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, tautomer or rotamer thereof, wherein

is independently selected from the group consisting of

14. A compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, tautomer or rotamer thereof, wherein R 4 is H, C 1-3 alkyl or Y, wherein the C 1-3 alkyl is substituted with tetrazolyl or tetrazolonyl, wherein the tetrazolyl or tetrazolonyl is optionally substituted with C 1-6 alkyl, C 1-6 hydroxyalkyl, or C 1-4 alkyl-O—C 1-4 alkyl wherein Y is selected from the group consisting of pyridinyl, pyrazolyl, and phenyl wherein the pyridinyl, pyrazolyl, and phenyl have from one to three substituents each of which is independently selected from —C 1-4 alkyl, —C 1-4 alkoxy and —CO 2 H.

15. A compound of claim 14 , or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, tautomer or rotamer thereof, wherein R 4 is selected from the group consisting of:

16. A compound of claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide, tautomer or rotamer thereof, wherein R 7 is selected from the group consisting of methyl, ethyl and CF 3 .

17. A compound of claim 1 , having the formula (A1):

wherein R 1a is selected from CH 3 and Cl; R 1b is absent or is CH 3 ; R 3 is H or D; R 4 is H or Y; R 5a and R 5b are each independently selected from H, F, Cl, Br and CH 3 ; R 6a and R 6b are each independently selected from H and CH 3 ; and R 7 is methyl or ethyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof.

18. A compound of claim 17 , or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein R 1a is CH 3 ; R 1b is absent or is CH 3 : R 3 is H or D; R 4 is H; R 5a is H, F, Me or Cl or Br; R 5b is H or F; R 6a and R 6b are each H; and R 7 is methyl or ethyl.

19. A compound of claim 17 , or a pharmaceutically acceptable salt, solvate, or hydrate thereof, which compound is substantially free of other isomers at the carbon atom bearing R 3 .

20. A compound of claim 17 , or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein R 4 is Y.

21. A compound of claim 1 , having the formula (A2):

wherein R 1a is selected from CH 3 and CI; R 1b is H or CH 3 ; R 3 is H or D; R 4a and R 4b are independently selected from halogen, —CN, —C 1-4 alkyl, —C 1-4 alkoxy, —C 1-4 hydroxyalkyl, —C 1-4 haloalkyl, OCF 3 , —CO 2 R a , —CONR a R b , —C(O)R a , —OC(O)NR a R b , —NR a C(O)R b , —CH 2 CO 2 R a , and R a and R b are independently selected from hydrogen, C 1-4 alkyl, C 1-4 hydroxyalkyl and C 1-4 haloalkyl; R 5a and R 5b are each independently selected from H, F, Cl, Br and CH 3 ; R 6a and R 6b are each independently selected from H and CH 3 ; and R 7 is selected from the group consisting of methyl, ethyl and C 1-2 haloalkyl; or a pharmaceutically acceptable salt, solvate or hydrate thereof.

22. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, selected from the group consisting of

23. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

24. A pharmaceutical composition comprising a compound of claim 1 .

25. A method of treating a CXCR2- and/or CCR6-mediated disease or condition in a subject in need thereof, said method comprising administering an effective amount of a compound of claim 1 to said subject.

26. A method of claim 25 , wherein the disease or condition is an acute or chronic inflammatory disorder.

27. A method of claim 26 , wherein the acute or chronic inflammatory disorder is psoriasis, dry eye disease, atherosclerosis, discoid lupus erythematosus, rheumatoid arthritis, lupus, radiation induced fibrotic lung disease, autoimmune bullous dermatosis (AIBD), chronic obstructive pulmonary disease, or ozone-induced airway inflammation.

28. A method of claim 25 , wherein the disease is a cancer selected from the group consisting of cutaneous T-cell lymphoma, non-Hodgkin lymphoma, Mycosis fungoides, Pagetoid reticulosis, Sézary syndrome, Granulomatous slack skin, Lymphomatoid papulosis, Pityriasis lichenoides chronica, Pityriasis lichenoides et varioliformis acuta, CD30+ cutaneous T-cell lymphoma, Secondary cutaneous CD30+ large cell lymphoma, non-mycosis fungoides CD30 cutaneous large T-cell lymphoma, Pleomorphic T-cell lymphoma, Lennert lymphoma, subcutaneous T-cell lymphoma, angiocentric lymphoma, blastic NK-cell lymphoma, B-cell Lymphomas, hodgkins Lymphoma (HL), Head and neck tumor; Squamous cell carcinoma, rhabdomyocarcoma, Lewis lung carcinoma (LLC), non-small cell lung cancer, esophageal squamous cell carcinoma, esophageal adenocarcinoma, renal cell carcinoma (RCC), colorectal cancer (CRC), acute myeloid leukemia (AML), breast cancer, gastric cancer, prostatic small cell neuroendocrine carcinoma (SCNC), liver cancer, glioblastoma, liver cancer, oral squamous cell carcinoma, pancreatic cancer, thyroid papillary cancer, intrahepatic cholangiocellular carcinoma, hepatocellular carcinoma, bone cancer, metastasis, and nasopharyngeal carcinoma.

29. A method of claim 28 , wherein the compound is used alone or in combination with one or more other anti-cancer therapies.

30. A method of claim 29 , wherein the compound is used in combination with one or more other anti-cancer therapies, wherein said one or more other anticancer therapies are selected from the group consisting of a cytotoxic chemotherapy, an anti-cancer vaccine, an anti-tumor vaccine, an anti-immunocytokine therapy, an immunocytokine therapy, a checkpoint inhibitor, and a chimeric antigen receptor (CAR) T cell immunotherapeutic agent, and gene transfer therapy.

31. A method of claim 29 , wherein the one or more other anti-cancer therapy is selected from the group consisting of: drugs that block the activity of CTLA-4 (CD152), PD-1 (CD279), PDL-1 (CD274), TIM-3, LAG-3 (CD223), VISTA, KIR, NKG2A, BTLA, PD-1H, TIGIT, CD96, 4-1BB (CD137), 4-1BBL (CD137L), GARP, CSF-1R, A2AR, CD73, CD47, tryptophan 2,3-dioxygenase (TDO) or indoleamine 2,3 dioxygenase (IDO), and agonists of OX40, GITR, 4-1BB, ICOS, STING or CD40.

32. A method of claim 27 wherein the compound is used alone or in combination with one or more other therapeutic agents.

33. A method of claim 32 , wherein the compound is used in combination with one or more of a corticosteroid, a retinoid-like agent, an antineoplastics, and interferons analogs, TNF alpha ligand inhibitor, a TNF binding agent, an IL-1 ligand inhibitor; an IL-6 ligand inhibitor, an IL-8 ligand inhibitor; an IL-17 antagonist, a TNF antagonist, a Retinoic acid receptor gamma antagonist, an IL-17A ligand inhibitor; an IL-17F ligand inhibitor, a sphingosine-1-phosphate receptor-1 antagonist, a sphingosine-1-phosphate receptor-1 modulator, an IL-12 antagonist; an IL-23 antagonist, a type II TNF receptor modulator, an IL-23A inhibitor, a PDE 4 inhibitor, a JAK tyrosine kinase inhibitor, a Jak1 tyrosine kinase inhibitor; a Jak3 tyrosine kinase inhibitor, a Retinoic acid receptor agonist, a Sphingosine-1-phosphate receptor-1 modulator, a TLR-7 antagonist, a TLR-8 antagonist a TLR-9 antagonist, or an IL-8 antagonist.